# CNS Pharmaceuticals, Inc.: overview CNSP · Nasdaq · CIK 1729427 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cnsp.md) · [Financials](/companies/cnsp/financials.md) · [Filings](/companies/cnsp/filings.md) · [Insiders](/companies/cnsp/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(153.20)](/filings/0001683168-25-008466.md) | not reported | [(18.93)](/filings/0001683168-26-003847.md) | [(6.42)](/filings/0001683168-26-006224.md) | [(5.76)](/filings/0001683168-25-008466.md) | not reported | [(7.30)](/filings/0001683168-26-003847.md) | [(0.38)](/filings/0001683168-26-006224.md) | | Free cash flow | $k | not reported | [(5,475) d](/filings/0001683168-26-002550.md) | [(3,242)](/filings/0001683168-26-003847.md) | [(5,344) d](/filings/0001683168-26-006224.md) | not reported | not reported | [(4,655)](/filings/0001683168-26-003847.md) | [(3,543) d](/filings/0001683168-26-006224.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(16.50)](/filings/0001683168-23-002086.md) | [(11.22)](/filings/0001683168-24-002032.md) | [(12509.11)](/filings/0001683168-25-002139.md) | [(466.89)](/filings/0001683168-26-002550.md) | [(35.75)](/filings/0001683168-26-002550.md) | | Free cash flow | $m | [(13.5)](/filings/0001683168-23-002086.md) | [(10.6)](/filings/0001683168-24-002032.md) | [(14.1)](/filings/0001683168-25-002139.md) | [(17.1)](/filings/0001683168-26-002550.md) | [(13.8)](/filings/0001683168-26-002550.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cnsp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $649.3k | 135,830 | | Added +90,000 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $334.6k | 70,000 | | New +70,000 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $198.7k | 41,573 | | Reduced −19,427 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $64.6k | 13,524 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $48.9k | 10,226 | | New +10,226 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $33.4k | 6,993 | | New +6,993 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $7.0k | 1,461 | | Added +732 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $3.8k | 799 | | Reduced −511 | | [BARCLAYS PLC](/funds/312069.md) | 2026-06-30 | $91 | 19 | | New +19 | | [BARRETT & COMPANY, INC.](/funds/887602.md) | 2026-06-30 | $38 | 8 | | Unchanged | ## Recent filings [All 390 filings](/companies/cnsp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-02 | 12:00 ET | [8-K](/filings/0001683168-26-007552.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001683168-26-007552 | | 2026-08-21 | 21:15 ET | [DEF 14A](/filings/0001683168-26-006660.md) | Proxy statement, period 2026-09-30 | 0001683168-26-006660 | | 2026-08-12 | 11:56 ET | [10-Q](/filings/0001683168-26-006224.md) | Quarterly report, period 2026-06-30 | 0001683168-26-006224 | | 2026-07-02 | 11:30 ET | [8-K](/filings/0001683168-26-005233.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-005233 | | 2026-05-14 | 11:55 ET | [10-Q](/filings/0001683168-26-003847.md) | Quarterly report, period 2026-03-31 | 0001683168-26-003847 | | 2026-05-04 | 11:05 ET | [8-K](/filings/0001683168-26-003432.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001683168-26-003432 | | 2026-04-30 | 20:30 ET | [10-K/A](/filings/0001683168-26-003374.md) | Annual report, amended, period 2025-12-31 | 0001683168-26-003374 | | 2026-03-31 | 20:30 ET | [10-K](/filings/0001683168-26-002550.md) | Annual report, period 2025-12-31 | 0001683168-26-002550 | | 2026-03-11 | 12:35 ET | [8-K](/filings/0001683168-26-001664.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001683168-26-001664 | | 2026-03-02 | 22:00 ET | [8-K](/filings/0001683168-26-001413.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001683168-26-001413 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001683168-26-002550.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1729427 - Tickers: CNSP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.